James O. Kahn

7.6k total citations · 1 hit paper
70 papers, 5.8k citations indexed

About

James O. Kahn is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, James O. Kahn has authored 70 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Infectious Diseases, 47 papers in Virology and 18 papers in Epidemiology. Recurrent topics in James O. Kahn's work include HIV Research and Treatment (47 papers), HIV/AIDS Research and Interventions (44 papers) and HIV/AIDS drug development and treatment (33 papers). James O. Kahn is often cited by papers focused on HIV Research and Treatment (47 papers), HIV/AIDS Research and Interventions (44 papers) and HIV/AIDS drug development and treatment (33 papers). James O. Kahn collaborates with scholars based in United States, Russia and United Kingdom. James O. Kahn's co-authors include Bruce D. Walker, Frederick Hecht, Margaret A. Chesney, Jay A. Levy, Jeffrey N. Martin, Steven G. Deeks, Sally Blower, Michael S. McGrath, Paul A. Volberding and Robert M. Grant and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

James O. Kahn

69 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load

2004 605 citations Steven G. Deeks, Amy Narvaez et al. profile →

Peers

James O. Kahn

VIROL

EPIDE

IMMUN

Phyllis J. Kanki United States

Richard Marlink United States

C. Rouzioux France

Suzanne Jurriaans Netherlands

Roland Tubiana France

Richard T. D’Aquila United States

Keith Henry United States

Fred Valentine United States

Homayoon Farzadegan United States

Cécile Tremblay Canada

Phyllis J. Kanki United States

James O. Kahn

3.5k ×1.0

3.6k ×1.0

VIROL

1.7k ×1.0

EPIDE

1.2k ×0.9

IMMUN

352 ×0.7

Citations per year, relative to James O. Kahn James O. Kahn (= 1×) peers Phyllis J. Kanki

Countries citing papers authored by James O. Kahn

Since Specialization

Citations

This map shows the geographic impact of James O. Kahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James O. Kahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James O. Kahn more than expected).

Fields of papers citing papers by James O. Kahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James O. Kahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James O. Kahn. The network helps show where James O. Kahn may publish in the future.

Co-authorship network of co-authors of James O. Kahn

This figure shows the co-authorship network connecting the top 25 collaborators of James O. Kahn. A scholar is included among the top collaborators of James O. Kahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James O. Kahn. James O. Kahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muñoz, Mónica, Wei Liu, Joseph A. Delaney, et al.. (2013). Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care. JAIDS Journal of Acquired Immune Deficiency Syndromes. 64(3). 254–260. 16 indexed citations

Geng, Elvin, C. Bradley Hare, James O. Kahn, et al.. (2012). The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/ L in a Public Health Setting. Clinical Infectious Diseases. 55(12). 1690–1697. 24 indexed citations

Roland, Michelle E., Torsten B. Neilands, M R Krone, et al.. (2005). Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Clinical Infectious Diseases. 41(10). 1507–1513. 100 indexed citations

Roland, Michelle E., Tarek Elbeik, James O. Kahn, et al.. (2004). HIV RNA Testing in the Context of Nonoccupational Postexposure Prophylaxis. The Journal of Infectious Diseases. 190(3). 598–604. 11 indexed citations

Barbour, Jason D., Frederick Hecht, Terri Wrin, et al.. (2004). Higher CD4⁺T Cell Counts Associated with Low ViralpolReplication Capacity among Treatment‐Naive Adults in Early HIV‐1 Infection. The Journal of Infectious Diseases. 190(2). 251–256. 57 indexed citations

Pinkerton, Steven D., Jeffrey N. Martin, Michelle E. Roland, et al.. (2004). Cost-effectiveness of Postexposure Prophylaxis After Sexual or Injection-Drug Exposure to Human Immunodeficiency Virus. Archives of Internal Medicine. 164(1). 46–46. 50 indexed citations

Shiboski, Steve, et al.. (2004). Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS. 18(15). 1991–1999. 14 indexed citations

Hare, C. Bradley & James O. Kahn. (2004). Primary HIV infection. Current Infectious Disease Reports. 6(1). 65–71. 4 indexed citations

Smith, Don, Gilbert R. Kaufmann, James O. Kahn, et al.. (2003). Greater Reversal of CD4 ⁺ Cell Abnormalities and Viral Load Reduction after Initiation of Antiretroviral Therapy with Zidovudine, Lamivudine, and Nelfinavir before Complete HIV Type 1 Seroconversion. AIDS Research and Human Retroviruses. 19(3). 189–199. 11 indexed citations

10.

Altfeld, Marcus, Marylyn M. Addo, Eric Rosenberg, et al.. (2003). Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 17(18). 2581–2591. 280 indexed citations

11.

Narvaez, Amy, Rongzhen Zhang, James O. Kahn, et al.. (2002). Increased HLA-DR Expression on Peripheral Blood Monocytes in Subsets of Subjects With Primary HIV Infection Is Associated With Elevated CD4 T-Cell Apoptosis and CD4 T-Cell Depletion. JAIDS Journal of Acquired Immune Deficiency Syndromes. 30(2). 146–153. 26 indexed citations

12.

McGrath, Michael S., James O. Kahn, & Brian Herndier. (2002). Development of WF10, a novel macrophage-regulating agent.. PubMed. 3(3). 365–73. 22 indexed citations

13.

Huff, Joel R. & James O. Kahn. (2001). Discovery and clinical development of HIV-1 protease inhibitors. Advances in protein chemistry. 56. 213–251. 14 indexed citations

14.

Roland, Michelle E., Jeffrey N. Martin, Robert M. Grant, et al.. (2001). Postexposure Prophylaxis for Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: Identification and Characterization of the Source of Exposure. The Journal of Infectious Diseases. 184(12). 1608–1612. 22 indexed citations

15.

Chesney, Margaret A., Donald B. Chambers, & James O. Kahn. (1997). Risk Behavior for HIV Infection in Participants in Preventive HIV Vaccine Trials: A Cautionary Note. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 16(4). 266–271. 125 indexed citations

16.

Spino, Cathie, James O. Kahn, Raphael Dolin, & John Phair. (1997). Predictors of Survival in HIV-Infected Persons With 50 or Fewer CD4 Cells/mm3. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 15(5). 346–355. 17 indexed citations

17.

Zolla‐Pazner, Susan, Carl R. Alving, Robert B. Belshe, et al.. (1997). Neutralization of a Clade B Primary Isolate by Sera from Human Immunodeficiency Virus—Uninfected Recipients of Candidate AIDS Vaccines. The Journal of Infectious Diseases. 175(4). 764–774. 39 indexed citations

18.

Welles, Seth L., J. Brooks Jackson, Belinda Yen‐Lieberman, et al.. (1996). Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-l) RNA Levels in Patients with Advanced HIV-l Disease and with Little or No Prior Zidovudine Therapy. The Journal of Infectious Diseases. 174(4). 696–703. 74 indexed citations

19.

Aweeka, Francesca, Amira Al‐Uzri, Katrin Peter, et al.. (1995). Oral and Intravenous Zidovudine Pharmacokinetics: The Effect of Granulocyte‐Macrophage Colony Stimulating Factor. The Journal of Clinical Pharmacology. 35(9). 856–864. 4 indexed citations

20.

Garcia, Paul A., Harry V. Vinters, Rachel Williams, et al.. (1993). Neurological reactions in HIV‐infected patients treated with trichosanthin. Neuropathology and Applied Neurobiology. 19(5). 402–405. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact